SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease | MicrobiomeTrials← Back to trialsNCT05900882
SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2022-07-15Est. Completion: 2026-08-30
Enrollment target: 29 participants Locations- Changzhou Second People's Hospital, Changzhou, Jiangsu, China
- Nanjing First People's Hospital, Nanjing, Jiangsu, China
- The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
- Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
- Taizhou People's Hospital, Taizhou, Jiangsu, China
- Yancheng First People's Hospital, Yancheng, Jiangsu, China
Other microbiome trials you might be interested in
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
Background:
Multiple myeloma (MM) is a type of blood cancer that affects a person s immunity. MM returns after treatmen…
Bethesda, United StatesCompleted Jan 1, 2033
Extramedullary Disease in Multiple MyelomaMultiple Myeloma
This phase I/II trial tests the safety and effectiveness of extramedullary disease (EMD)-directed external beam radiatio…
Duarte, United StatesCompleted Jan 18, 2030
CardiotoxicityCancerCardiac ArrhythmiaLeft Ventricular DysfunctionBreast CancerMultiple Myeloma
This pilot study will evaluate the validity and feasibility of ambulatory cardiac monitoring to identify markers of card…
Minneapolis, United StatesEst. completion Mar 1, 2028